{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:35:04Z","timestamp":1795008904390,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41401-023-01106-6","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T09:02:36Z","timestamp":1684918956000},"page":"2065-2074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Fisetin treatment alleviates kidney injury in mice with diabetes-exacerbated atherosclerosis through inhibiting CD36\/fibrosis pathway"],"prefix":"10.1038","volume":"44","author":[{"given":"Ting-feng","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-chang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-tong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-jun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-zhong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou-ling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-hong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","volume":"87","author":"JE Shaw","year":"2010","unstructured":"Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pr. 2010;87:4\u201314.","journal-title":"Diabetes Res Clin Pr"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pr. 2018;138:271\u201381.","journal-title":"Diabetes Res Clin Pr"},{"key":"1106_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryden L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25\u201332.","journal-title":"Eur J Prev Cardiol"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459\u2013502.","journal-title":"Circulation"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc22-Sint","volume":"45","author":"American Diabetes A.","year":"2022","unstructured":"American Diabetes A. Introduction: Standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S1\u2013S2.","journal-title":"Diabetes Care"},{"key":"1106_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","volume":"2067","author":"MK Sagoo","year":"2020","unstructured":"Sagoo MK, Gnudi L. Diabetic nephropathy: An overview. Methods Mol Biol. 2020;2067:3\u20137.","journal-title":"Methods Mol Biol"},{"key":"1106_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.semnephrol.2007.01.006","volume":"27","author":"AL Tan","year":"2007","unstructured":"Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27:130\u201343.","journal-title":"Semin Nephrol"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ki.2014.67","volume":"86","author":"SY Li","year":"2014","unstructured":"Li SY, Huang PH, Yang AH, Tarng DC, Yang WC, Lin CC, et al. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int. 2014;86:358\u201369.","journal-title":"Kidney Int"},{"key":"1106_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1755-5922.2010.00218.x","volume":"30","author":"AA Elmarakby","year":"2012","unstructured":"Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30:49\u201359.","journal-title":"Cardiovasc Ther"},{"key":"1106_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00795-016-0146-3","volume":"50","author":"T Tanaka","year":"2017","unstructured":"Tanaka T. A mechanistic link between renal ischemia and fibrosis. Med Mol Morphol. 2017;50:1\u20138.","journal-title":"Med Mol Morphol"},{"key":"1106_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/01.ASN.0000065640.77499.D7","volume":"14","author":"RM Mason","year":"2003","unstructured":"Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358\u201373.","journal-title":"J Am Soc Nephrol"},{"key":"1106_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ki.2011.86","volume":"80","author":"Y Tomino","year":"2011","unstructured":"Tomino Y, Hagiwara S, Gohda T. AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction. Kidney Int. 2011;80:133\u20135.","journal-title":"Kidney Int"},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"105019","DOI":"10.1016\/j.meegid.2021.105019","volume":"94","author":"MA Abo-Kadoum","year":"2021","unstructured":"Abo-Kadoum MA, Assad M, Uae M, Nzaou SAE, Gong Z, Moaaz A, et al. Mycobacterium tuberculosis RKIP (Rv2140c) dephosphorylates ERK\/NF-kappaB upstream signaling molecules to subvert macrophage innate immune response. Infect Genet Evol. 2021;94:105019.","journal-title":"Infect Genet Evol"},{"key":"1106_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrneph.2017.126","volume":"13","author":"X Yang","year":"2017","unstructured":"Yang X, Okamura DM, Lu X, Chen Y, Moorhead J, Varghese Z, et al. CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol. 2017;13:769\u201381.","journal-title":"Nat Rev Nephrol"},{"key":"1106_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/jcb.21236","volume":"101","author":"YL Yang","year":"2007","unstructured":"Yang YL, Lin SH, Chuang LY, Guh JY, Liao TN, Lee TC, et al. CD36 is a novel and potential anti-fibrogenic target in albumin-induced renal proximal tubule fibrosis. J Cell Biochem. 2007;101:735\u201344.","journal-title":"J Cell Biochem"},{"key":"1106_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199\u2013210.","journal-title":"J Pathol"},{"key":"1106_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/ars.2012.4901","volume":"19","author":"N Khan","year":"2013","unstructured":"Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: A dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19:151\u201362.","journal-title":"Antioxid Redox Signal"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ebiom.2018.09.015","volume":"36","author":"MJ Yousefzadeh","year":"2018","unstructured":"Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18\u201328.","journal-title":"EBioMedicine"},{"key":"1106_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejphar.2014.06.065","volume":"740","author":"GS Prasath","year":"2014","unstructured":"Prasath GS, Pillai SI, Subramanian SP. Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats. Eur J Pharmacol. 2014;740:248\u201354.","journal-title":"Eur J Pharmacol"},{"key":"1106_CR20","doi-asserted-by":"publisher","first-page":"107353","DOI":"10.1016\/j.intimp.2020.107353","volume":"92","author":"G Chenxu","year":"2021","unstructured":"Chenxu G, Xianling D, Qin K, Linfeng H, Yan S, Mingxin X, et al. Fisetin protects against high fat diet-induced nephropathy by inhibiting inflammation and oxidative stress via the blockage of iRhom2\/NF-kappaB signaling. Int Immunopharmacol. 2021;92:107353.","journal-title":"Int Immunopharmacol"},{"key":"1106_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lfs.2019.02.017","volume":"221","author":"OY Althunibat","year":"2019","unstructured":"Althunibat OY, Al Hroob AM, Abukhalil MH, Germoush MO, Bin-Jumah M, Mahmoud AM. Fisetin ameliorates oxidative stress, inflammation and apoptosis in diabetic cardiomyopathy. Life Sci. 2019;221:83\u201392.","journal-title":"Life Sci"},{"key":"1106_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0107-x","volume":"7","author":"Y Liang","year":"2018","unstructured":"Liang Y, Han H, Liu L, Duan Y, Yang X, Ma C, et al. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. Oncogenesis. 2018;7:98.","journal-title":"Oncogenesis"},{"key":"1106_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.atherosclerosis.2019.01.025","volume":"282","author":"X Liu","year":"2019","unstructured":"Liu X, Li J, Liao J, Wang H, Huang X, Dong Z, et al. Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic LDLR\u2212\/\u2212 mice. Atherosclerosis. 2019;282:100\u20139.","journal-title":"Atherosclerosis"},{"key":"1106_CR24","doi-asserted-by":"publisher","first-page":"109389","DOI":"10.1016\/j.biopha.2019.109389","volume":"118","author":"S Yang","year":"2019","unstructured":"Yang S, Chen Y, Duan Y, Ma C, Liu L, Li Q, et al. Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db\/db mice. Biomed Pharmacother. 2019;118:109389.","journal-title":"Biomed Pharmacother"},{"key":"1106_CR25","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.2337\/dc12-2572","volume":"36","author":"EI Ekinci","year":"2013","unstructured":"Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36:3620\u20136.","journal-title":"Diabetes Care"},{"key":"1106_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1096\/fj.02-0089fje","volume":"16","author":"L Guo","year":"2002","unstructured":"Guo L, Wu C. Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB J. 2002;16:1298\u2013300.","journal-title":"FASEB J"},{"key":"1106_CR27","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/ndt\/gfl113","volume":"21","author":"HA Shui","year":"2006","unstructured":"Shui HA, Ka SM, Lin JC, Lee JH, Jin JS, Lin YF, et al. Fibronectin in blood invokes the development of focal segmental glomerulosclerosis in mouse model. Nephrol Dial Transpl. 2006;21:1794\u2013802.","journal-title":"Nephrol Dial Transpl"},{"key":"1106_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707\u201316.","journal-title":"J Clin Invest"},{"key":"1106_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2009.10.022","volume":"87","author":"J Su","year":"2010","unstructured":"Su J, Li SJ, Chen ZH, Zeng CH, Zhou H, Li LS, et al. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms\u2019 tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pr. 2010;87:167\u201375.","journal-title":"Diabetes Res Clin Pr"},{"key":"1106_CR30","doi-asserted-by":"publisher","first-page":"F905","DOI":"10.1152\/ajprenal.00421.2006","volume":"292","author":"JM Catania","year":"2007","unstructured":"Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Ren Physiol. 2007;292:F905\u201311.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1106_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.redox.2018.09.025","volume":"20","author":"T Yuan","year":"2019","unstructured":"Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247\u201360.","journal-title":"Redox Biol"},{"key":"1106_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semnephrol.2012.04.002","volume":"32","author":"HY Lan","year":"2012","unstructured":"Lan HY, Chung AC. TGF-beta\/Smad signaling in kidney disease. Semin Nephrol. 2012;32:236\u201343.","journal-title":"Semin Nephrol"},{"key":"1106_CR33","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1042\/CS20180306","volume":"132","author":"GR Geovanini","year":"2018","unstructured":"Geovanini GR, Libby P. Atherosclerosis and inflammation: Overview and updates. Clin Sci (Lond). 2018;132:1243\u201352.","journal-title":"Clin Sci (Lond)"},{"key":"1106_CR34","doi-asserted-by":"publisher","first-page":"5570885","DOI":"10.1155\/2021\/5570885","volume":"2021","author":"Y Hada","year":"2021","unstructured":"Hada Y, Uchida HA, Wada J. Fisetin attenuates lipopolysaccharide-induced inflammatory responses in macrophage. Biomed Res Int. 2021;2021:5570885.","journal-title":"Biomed Res Int"},{"key":"1106_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00011-014-0750-4","volume":"63","author":"S Kwak","year":"2014","unstructured":"Kwak S, Ku SK, Bae JS. Fisetin inhibits high-glucose-induced vascular inflammation in vitro and in vivo. Inflamm Res. 2014;63:779\u201387.","journal-title":"Inflamm Res"},{"key":"1106_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.bbalip.2008.06.009","volume":"1781","author":"TW Lian","year":"2008","unstructured":"Lian TW, Wang L, Lo YH, Huang IJ, Wu MJ. Fisetin, morin and myricetin attenuate CD36 expression and oxLDL uptake in U937-derived macrophages. Biochim Biophys Acta. 2008;1781:601\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"1106_CR37","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1097\/FJC.0000000000001096","volume":"78","author":"JF Varghese","year":"2021","unstructured":"Varghese JF, Patel R, Singh M, Yadav UCS. Fisetin prevents oxidized low-density lipoprotein-induced macrophage foam cell formation. J Cardiovasc Pharmacol. 2021;78:e729\u2013e37.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1106_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biochi.2019.06.007","volume":"163","author":"R Patel","year":"2019","unstructured":"Patel R, Varghese JF, Singh RP, Yadav UCS. Induction of endothelial dysfunction by oxidized low-density lipoproteins via downregulation of Erk-5\/Mef2c\/KLF2 signaling: Amelioration by fisetin. Biochimie. 2019;163:152\u201362.","journal-title":"Biochimie"},{"key":"1106_CR39","first-page":"25","volume":"21","author":"L Yan","year":"2021","unstructured":"Yan L, Jia Q, Cao H, Chen C, Xing S, Huang Y, et al. Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE\u2212\/\u2212 mice. Exp Ther Med. 2021;21:25.","journal-title":"Exp Ther Med"},{"key":"1106_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbrc.2022.07.031","volume":"622","author":"M Xu","year":"2022","unstructured":"Xu M, Wu X, Liu Z, Ding Y, Kong W, Little PJ, et al. A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db\/db mice. Biochem Biophys Res Commun. 2022;622:163\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1106_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ndt\/gfs387","volume":"28","author":"Y Takamiya","year":"2013","unstructured":"Takamiya Y, Fukami K, Yamagishi S, Kaida Y, Nakayama Y, Obara N, et al. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transpl. 2013;28:55\u201362.","journal-title":"Nephrol Dial Transpl"},{"key":"1106_CR42","doi-asserted-by":"crossref","unstructured":"Wang L, Wang HL, Liu TT, Lan HY. TGF-beta as a master regulator of diabetic nephropathy. Int J Mol Sci 2021;22:7881.","DOI":"10.3390\/ijms22157881"},{"key":"1106_CR43","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1073\/pnas.90.5.1814","volume":"90","author":"T Yamamoto","year":"1993","unstructured":"Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA. 1993;90:1814\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1106_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1440-1681.2007.04875.x","volume":"35","author":"K Jandeleit-Dahm","year":"2008","unstructured":"Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE\/RAGE axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol. 2008;35:329\u201334.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1106_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.intimp.2015.11.014","volume":"29","author":"SH Seo","year":"2015","unstructured":"Seo SH, Jeong GS. Fisetin inhibits TNF-alpha-induced inflammatory action and hydrogen peroxide-induced oxidative damage in human keratinocyte HaCaT cells through PI3K\/AKT\/Nrf-2-mediated heme oxygenase-1 expression. Int Immunopharmacol. 2015;29:246\u201353.","journal-title":"Int Immunopharmacol"},{"key":"1106_CR46","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41401-020-0462-y","volume":"41","author":"HF Zhang","year":"2020","unstructured":"Zhang HF, Zhang HB, Wu XP, Guo YL, Cheng WD, Qian F. Fisetin alleviates sepsis-induced multiple organ dysfunction in mice via inhibiting p38 MAPK\/MK2 signaling. Acta Pharmacol Sin. 2020;41:1348\u201356.","journal-title":"Acta Pharmacol Sin"},{"key":"1106_CR47","doi-asserted-by":"crossref","unstructured":"Marechal L, Laviolette M, Rodrigue-Way A, Sow B, Brochu M, Caron V, et al. The CD36-PPARgamma pathway in metabolic disorders. Int J Mol Sci 2018;19:1529.","DOI":"10.3390\/ijms19051529"},{"key":"1106_CR48","doi-asserted-by":"publisher","first-page":"16977","DOI":"10.1074\/jbc.M116.740092","volume":"291","author":"M Yu","year":"2016","unstructured":"Yu M, Jiang M, Chen Y, Zhang S, Zhang W, Yang X, et al. Inhibition of macrophage CD36 expression and cellular oxidized low density lipoprotein (oxLDL) accumulation by tamoxifen: a peroxisome proliferator-activated receptor (PPAR)gamma-dependent mechanism. J Biol Chem. 2016;291:16977\u201389.","journal-title":"J Biol Chem"},{"key":"1106_CR49","doi-asserted-by":"publisher","first-page":"21788","DOI":"10.1074\/jbc.M115.654582","volume":"290","author":"X Yang","year":"2015","unstructured":"Yang X, Yao H, Chen Y, Sun L, Li Y, Ma X, et al. Inhibition of glutathione production induces macrophage CD36 expression and enhances cellular-oxidized low density lipoprotein (oxLDL) uptake. J Biol Chem. 2015;290:21788\u201399.","journal-title":"J Biol Chem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01106-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:04:50Z","timestamp":1696233890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01106-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1038\/s41401-023-01106-6","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"8 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}